

BMJ Open *Pseudomonas aeruginosa* isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study

Hong Wang,^{1,2} Xiao-Bin Ji,¹ Bei Mao,¹ Cheng-Wei Li,¹ Hai-Wen Lu,¹ Jin-Fu Xu¹

To cite: Wang H, Ji X-B, Mao B, et al. *Pseudomonas aeruginosa* isolation in patients with non-cystic fibrosis bronchiectasis: a retrospective study. *BMJ Open* 2018;**8**:e014613. doi:10.1136/bmjopen-2016-014613

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-014613>).

HW, X-BJ and BM contributed equally.

Received 10 October 2016
Revised 16 February 2018
Accepted 16 February 2018



¹Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

²Department of respiratory internal medicine, Suzhou Science and Technology Town Hospital, Suzhou, China

Correspondence to
Professor Jin-Fu Xu;
jfxucn@gmail.com

ABSTRACT

Objectives *Pseudomonas aeruginosa* (*P. aeruginosa*) occupies an important niche in the pathogenic microbiome of bronchiectasis. The objective of this study is to evaluate the clinical characteristics and prognostic value of *P. aeruginosa* in Chinese adult patients with bronchiectasis. **Methods** This retrospective and follow-up study enrolled 1188 patients diagnosed with bronchiectasis at Shanghai Pulmonary Hospital between January 2011 and December 2012. The patients' clinical data including anthropometry, clinical symptoms, serum biomarkers, radiographic manifestations and lung function indices were reviewed. The median follow-up duration (IQR) was 44 (40–54) months, during which 289 patients were lost to follow-up. Data from 899 patients were collected and analysed for the outcomes of mortality, annual exacerbation frequency and health-related quality of life.

Results *P. aeruginosa* was isolated from 232 patients, alongside other pathogens such as *Aspergillus* (n=75) and *Candida albicans* (n=72). There were 74 deaths (12% of patients with *P. aeruginosa*, 7.3% of those without) over the course of the follow-up. The isolation of *P. aeruginosa* was a risk factor for all-cause mortality (HR, 3.07; 95% CI 1.32 to 7.15) and was associated with high rates of exacerbations (ie, ≥ 3 exacerbations per year of follow-up) (HR, 2.40; 95% CI 1.20 to 4.79). Patients with *P. aeruginosa* also had worse scores on the Hospital Anxiety and Depression Scale (anxiety, p=0.005; depression, p<0.001), the Leicester Cough Questionnaire (p=0.033) and the modified Medical Research Council scale (p=0.001) compared with those without *P. aeruginosa*.

Conclusions Isolation of *P. aeruginosa* in patients with bronchiectasis is a significant prognostic indicator and should be a major factor in the clinical management of the disease.

INTRODUCTION

Bronchiectasis is a chronic inflammatory respiratory disease defined as the irreversible dilatation of one or more bronchi.¹ Predisposed individuals can develop robust inflammatory responses to tissue injuries and bacterial infections, which may contribute to structural damage. The structural abnormalities of the airways lead to abnormal mucus clearance and further bacterial colonisation and finally form a vicious cycle.² Recent

Strengths and limitations of this study

- This study enrolled 1188 patients with bronchiectasis from all over the country.
- We conducted a 44 (40–54)-month follow-up study along with detailed analytics related to primary clinical outcomes.
- It was a single-centre study in a specialised hospital.
- We failed to obtain the microbiological data during follow-up due to diversified and inevitable reasons.

studies have recognised the niche occupied by *Pseudomonas aeruginosa* in the pathogenic microbiome of patients with bronchiectasis, its instigation of rapid decline in lung function and its role in the development of more extensive radiographic features of the disease.^{3–9} Furthermore, two multidimensional grading schemes for bronchiectasis severity, the Bronchiectasis Severity Index and the FACED score, include colonisation by *P. aeruginosa* as a criterion for earlier death and more frequent exacerbations and hospitalisation.^{5,10}

Given the association between *P. aeruginosa* with poor clinical outcomes in patients with bronchiectasis, early detection of *P. aeruginosa* is of great importance. Early detection is facilitated by research on the pathogenic distribution and clinical outcomes of *P. aeruginosa*; however, few studies in this area have been conducted in Chinese populations. Therefore, we aim to evaluate the distribution, characteristics and prognostic value of *P. aeruginosa* using clinical and follow-up data collected from a specialised hospital in Shanghai, China.

METHODS AND MATERIALS

Study subjects

Our study examined inpatients diagnosed with bronchiectasis between January 2011 and December 2012 at Shanghai Pulmonary Hospital. Patients were excluded if they did

not receive a high-resolution CT (HRCT) chest scan at the hospital or if they lacked data from either sputum or bronchoalveolar lavage fluid (BALF) samples. In this study, the PA group was defined as those patients isolated with *P. aeruginosa* during their hospitalisation. Meanwhile, the non-PA group was defined as those patients without *P. aeruginosa*. We also divided patients into PA, others (other pathogens) and negative groups in our subgroup analysis. All data collections were performed by clinical physicians who were involved in the study. Written informed consent was obtained from all patients.

Diagnosis of bronchiectasis

The presence of bronchiectasis was confirmed through HRCT examination and patient clinical history by two physicians who were blinded to the patients' information. High-resolution images of the lungs were obtained at full inspiration at 1 mm collimation and 10 mm intervals from apex to base and were independently interpreted by hospital radiologists with extensive experience in bronchiectasis diagnosis, based on the criteria published by Naidich *et al.*¹¹ Small bronchiectasis features that were only visible in a single pulmonary segment and were unrelated to clinical features were judged to be negligible, as they are known to appear in a large proportion of the healthy population.¹²

Data collection

According to standardised protocol, data on the anthropometry, clinical symptoms, serum biomarkers, radiographic manifestations and lung function indices at a stable state, outcomes (mortality, annual exacerbation frequency of follow-up) and quality of life (modified Medical Research Council (mMRC), LCQ and HADS scores) of all patients were uniformly recorded over a median follow-up duration of 44 (40–54) months. Body mass index (BMI) data were also collected as recent research has suggested a correlation between BMI and bronchiectasis prognosis.^{10 13} Interleukin (IL-1, IL-6), interferon (IFN), white blood cell (WBC), C reactive protein (CRP), erythrocyte sedimentation rate (ESR) and CD4/CD8 levels were obtained as markers of systemic inflammation and patient's immune state. Arterial blood gas (ABG) analyses were performed at rest and on room air, with normal conditions defined as having a PaO₂ within 10.34–13.3 kPa (80–100 mm Hg) and a PaCO₂ within 4.65–5.98 kPa (35–45 mm Hg). Pulmonary function indices included forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC) and FEV₁/FVC. Dyspnoea was assessed using the mMRC scale, cough was assessed with the Leicester Cough Questionnaire (LCQ) and adverse psychological effects were assessed with the Hospital Anxiety and Depression Scale (HADS). Detailed procedures from this study are shown in figure 1.

Lower respiratory tract samples

Spontaneous sputum and BALF were collected from each patient during hospitalisation. These samples were




Figure 1 Flow diagram depicting patient selection and analysis. HRCT, high-resolution CT.

kept at 4°C before they were sent to the hospital laboratory for analysis no more than 3 hours following sample collection. To reduce the impact on the microbe and bacterium, we did not collect sputum samples from those patients who were on antibiotics within the 2 weeks before the study. Sputum samples were deemed eligible if they contained <10 squamous epithelial cells and >25 leucocytes per low-powered field.¹⁴ Bronchoalveolar lavage fluid was processed via semiquantitative culture with a positive threshold of 10⁴ CFU/mL.¹⁵ All samples were separated from saliva, Gram stained and homogenised. Diluted secretions were then plated on blood, chocolate, MacConkey agar and Sabouraud agar. All detection methods were performed in accordance with relevant testing standards.

Health-related quality of life

The physician-administered mMRC score is a grading system from 0 to 4 that rates the impact of dyspnoea on a patient's everyday activities.¹⁶ ΔmMRC is the difference between the initial and final mMRC values taken and represents the change in dyspnoea severity over the follow-up period.

The LCQ score is a self-administered 19-item questionnaire measuring the physical, psychological and social impacts of chronic cough. Its severity score ranges from 3 to 21, with lower scores indicating greater impairment.^{17 18} ΔLCQ is the difference between the initial and final LCQ values taken and represents the change in cough severity over the follow-up period.

During the follow-up period, patients were asked to complete the self-reported HADS questionnaire, which

measures the degree of anxiety and depression using 14 items, with a score of ≥ 11 indicating clinically significant anxiety or depression.¹⁹ In this study, we used the final HADS result for each patient.

Exacerbations

A bronchiectasis exacerbation was defined as an acute deterioration in one or more symptoms (increasing sputum volume or purulence, worsening dyspnoea, increased cough, declining lung function or increased fatigue/malaise) or the appearance of new symptoms (fever, pleurisy or haemoptysis requiring antibiotic treatment).¹

Survival analysis

All patients underwent follow-up evaluations every year after discharge through telephone or face-to-face interviews. A patient was considered lost to follow-up if we were unable to contact him or her at each follow-up for any reason. The endpoint of this study was all-cause mortality, which was evaluated over a median follow-up duration of 44 (40–54) months. The cause and date of death were obtained from hospital medical records for patients who died in the hospital or from official death certificates otherwise. Follow-up was completed on 31 December 2015.

Statistical analysis

All statistical analyses were performed with SPSS, V.22.0. Qualitative and quantitative variables were summarised as relative frequencies (percentages) and medians (interquartile ranges). In the univariate analysis, Student's t-test was used to compare groups that were normally distributed, and non-normally distributed variables were compared with the Mann-Whitney U test. Categorical variables were compared using the χ^2 test. A logistic regression model was used to determine the factors associated with high rates of exacerbations. A Cox proportional hazard regression model was used to assess factors associated with survival. Variables that presented statistically significant differences ($p < 0.05$) in the univariate analysis and variables that were of clinical interest were included as the independent variables in the first step. Then, we used the forward stepwise technique (Wald test) to remove variables with $p > 0.1$ from the final model. The dependent variable was survival time to all-cause mortality. Survival curves between groups were constructed according to the Kaplan-Meier method and were compared using the log-rank test. HRs and 95% CIs were also calculated for each independent variable, with $p < 0.05$ considered statistically significant.

RESULTS

After excluding 316 patients without sputum or BALF data and 154 patients without an HRCT scan, there were 1188 patients (median age 57 (48–64) years; 45.5% men)

Table 1 Microbiological characteristics of subjects with bronchiectasis

Pathogens	Numbers (N)	Percentage (%) [*]	Percentage (%) [†]
Total [*]	1188	–	–
Total [†]	536	45.12	–
Bacteriologic	–	–	–
<i>Pseudomonas aeruginosa</i>	232	19.53	43.28
<i>Klebsiella pneumoniae</i>	44	3.70	8.21
<i>Mycobacterium tuberculosis</i>	46	3.87	8.58
<i>Nontuberculous mycobacteria</i>	27	2.27	5.04
<i>Acinetobacter baumannii</i>	15	1.26	2.80
<i>Enterobacter cloacae</i>	13	1.09	2.43
<i>Stenotrophomonas maltophilia</i>	11	0.93	2.05
<i>Staphylococcus aureus</i>	7	0.59	1.31
<i>Escherichia coli</i>	6	0.51	1.12
Mycological	–	–	–
<i>Aspergillus</i>	75	6.31	13.99
<i>Candida albicans</i>	72	6.06	13.43
<i>Saccharomycetes</i>	5	0.42	0.93
Others	26	2.19	4.85
Indefinite	26	2.19	4.85

^{*}Indicates the patients included in this study.

[†]Indicates the patients who had positive sputum or bronchoalveolar tests. Other species include *Proteus penneri*, *Pseudomonas fluorescens/putida*, *Serratia marcescens*, *Alcaligenes xylosoxidans subsp.*, *Acinetobacter lwoffii*, *Enterobacter aerogenes*, *Candida tropicalis*, *Staphylococcus epidermidis* and *Enterococcus faecium*. Indefinite species include Gram-positive cocci and Gram-negative bacilli (not clear).

who were ultimately entered into our study. Overall, 536 (45.1%) patients tested positive for pathogenic micro-organisms. Of the 536 organisms, there were 437 (81.5%) organisms isolated from sputum alone, 44 (8.2%) from BALF alone and 55 (10.3%) from both. *P. aeruginosa* was the most common pathogen, detected in 232 (43.3%) patients, followed by *Aspergillus* in 75 (14.0%) patients and *Candida albicans* in 72 (13.4%) patients. Full details are shown in [table 1](#).

Next, we analysed the general characteristics of the entire patient sample, and the differences between PA (n=232) and non-PA (n=956) groups ([table 2](#)). Relative to the non-PA group, patients with *P. aeruginosa* tended to be women and have less extensive smoking histories, more purulent sputum expectoration, more haemoptysis, longer symptom duration, more bilateral and cystic HRCT involvement, fewer normal ABGs, greater systemic inflammation and worse lung function.

Table 2 General characteristics of patients with bronchiectasis with and without PA

Parameter	Whole group	PA	Non-PA	P values
Subject, n	1188	232	956	–
Sex, M/F, n	541/647	66/166	475/481	<0.001
Age, years	57 (48–64)	56 (47–64)	57 (49–65)	0.133
BMI, kg/m ²	21.5 (19.0–23.9)	21.4 (3.6)	21.5 (19.0–24.0)	0.476
Smoking history, n (%)	250 (21.0)	21 (9.1)	229 (24.0)	<0.001
Current smokers, n (%)	149 (12.5)	12 (5.2)	137 (14.3)	<0.001
Ex-smokers, n (%)	101 (8.5)	9 (3.9)	92 (9.6)	0.005
Previous pneumonia, n (%)	22 (1.9)	7 (3.4)	15 (1.6)	0.082
Previous tuberculosis, n (%)	193 (16.3)	36 (15.5)	157 (16.5)	0.723
Purulent sputum, n (%)	851 (71.9)	196 (84.5)	655 (68.8)	<0.001
Haemoptysis, n (%)	394 (33.3)	94 (40.5)	300 (31.5)	0.009
Onset of symptoms, years	4 (0–19)	14 (5–30)	3 (0–10)	<0.001
Length of hospitalisation, days	9 (7–12)	9 (7–12)	9 (7–12)	0.298
mMRC score	1 (0–2)	1 (0–2)	1 (0–1)	0.302
LCQ score	13 (11–15)	11 (9–13)	14 (11–16)	<0.001
HRCT involvement, U/B, n	399/749	43/183	356/566	<0.001
Cystic bronchiectasis, n (%)	559 (50.5)	171 (79.2)	388 (43.5)	<0.001
CD4/CD8, %	1.8 (1.2–2.5)	1.6 (1.2–2.4)	1.8 (1.2–2.6)	0.101
Normal ABG, %	640 (64.0%)	112 (48.7%)	528 (68.6%)	<0.001
IL-1, pg/mL	23 (18–32)	22 (17–33)	23 (18–32)	0.485
IL-6, pg/mL	36.0 (25.0–55.0)	50.0 (29.0–79.0)	34.0 (24.0–51.5)	<0.001
IFN, KU/L	15 (12–21)	15 (12–20)	15 (12–21)	0.989
WBC, 10 ⁹ /L	6.2 (4.9–8.1)	6.9 (5.5–9.1)	6.0 (4.8–7.8)	<0.001
CRP, IU/mL	5.3 (3.0–10.9)	6.5 (3.7–20.6)	4.7 (2.9–8.9)	<0.001
ESR, mm/H	28.5 (14.0–55.0)	47.0 (23.0–74.0)	26.0 (12.0–49.5)	<0.001
FVC% of predicted (%)	84.9 (67.1–98.8)	74.2 (22.8)	85.6 (21.1)	<0.001
FEV ₁ % of predicted (%)	72.8 (49.3–90.6)	55.3 (33.4–77.2)	75.4 (56.4–92.7)	<0.001
FEV ₁ /FVC (%)	86.6 (71.2–97.4)	75.6 (61.4–91.5)	88.3 (74.9–98.1)	<0.001

Data are presented as n (%) or median (IQR), unless otherwise stated.

ABG, arterial blood gas; BMI, body mass index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; IFN, interferon; IL-1, interleukin 1; IL-6, interleukin 6; LCQ, the Leicester Cough Questionnaire; mMRC, modified Medical Research Council; U/B, unilateral/bilateral; WBC, white blood cell.

Data on clinical outcomes recorded during follow-up are shown in [table 3](#). There were 899 (75.7%) patients with bronchiectasis who were followed up until the end of the study. The PA and non-PA groups presented significant differences in terms of mortality rate (deaths per person-year of observation) ($p=0.045$) and annual exacerbation frequency ($p<0.001$). Compared with the non-PA group, patients with *P. aeruginosa* improved less on LCQ scoring and showed greater mMRC deterioration, as well as scored higher on the HADS questionnaire.

Kaplan-Meier survival curves between patients in the PA group (n=183; 22 dead) and non-PA group (n=716; 52 dead) are shown in [figure 2A](#), with PA (n=183; 22 dead), negative (n=473; 29 dead) and others (n=243; 23 dead) in [figure 2B](#). The PA group had significantly higher rates of mortality than both the non-PA group (log

rank test; $p(a)=0.045$) and the negative group (log rank test; $p(b1)=0.017$), while the mortality between the PA group and the others group (log rank test; $p(b2)=0.414$) or the others group and the negative group (log rank test; $p(b3)=0.125$) showed no statistically significant differences.

[Tables 4 and 5](#) show the unadjusted and fully adjusted Cox regression analyses. We checked on the proportional hazards assumption and found that it was adequate. The PA group was found to have a significantly higher risk of all-cause mortality compared with either the non-PA (unadjusted HR, 1.65; 95% CI 1.01 to 2.72) group or the negative (unadjusted HR, 2.09; 95% CI 1.17 to 3.75) group. This did not change significantly in the fully adjusted model for either the non-PA group (fully adjusted HR, 3.07; 95% CI 1.32 to 7.15) or the negative group (fully

Table 3 Follow-up outcomes in patients with bronchiectasis with and without PA

Parameter	Whole group	PA	Non-PA	P values
Subject, n (%)	899	183 (20.4)	716 (79.6)	–
Person-years of observation	3369	689.5	2679.5	–
Mortality rate (deaths per person-year of observation)	74/3369	22/689.5	52/2679.5	0.045
Annual exacerbation frequency	1.1 (1.2)	1.8 (1.3)	1.0 (1.1)	<0.001
ΔmMRC score	0.0 (1.0)	0.2 (1.0)	–0.1 (0.9)	0.001
Δ LCQ score	3.2 (2.7)	2.7 (2.7)	3.2 (2.7)	0.033
HADS score (anxiety)	4.6 (2.3)	4.9 (1.9)	4.6 (2.4)	0.005
HADS score (depression)	4.9 (2.2)	5.6 (1.9)	4.7 (2.3)	<0.001

Data are presented as n (%) or median (IQR), unless otherwise stated.

HADS, Hospital Anxiety and Depression Scale; ΔLCQ, the difference between follow-up and initial LCQ values; ΔmMRC, the difference between follow-up and initial mMRC values; mMRC, modified Medical Research Council; PA, *Pseudomonas aeruginosa*.

adjusted HR, 3.84; 95% CI 1.17 to 12.62). Besides, both tables showed that all-cause mortality was associated with increasing age and decreasing BMI in the fully adjusted models. In addition, when we used the backwards stepwise elimination procedure in statistical analysis, it can be found that patients with bronchiectasis who have longer duration of symptoms (fully adjusted HR, 1.03; 95% CI 1.01 to 1.04) and lower FEV₁ of predicted (%) (fully adjusted HR, 0.99; 95% CI 0.98 to 1.00) would suffer more mortality (online Supplementary table S1). Moreover, high mMRC scores (fully adjusted HR, 1.15; 95% CI 1.01 to 1.30) and lower FEV₁ of predicted (%) (fully adjusted HR, 0.99; 95% CI 0.98 to 1.00) were associated with more deaths among the patients with PA or negative PA (online Supplementary table S2).

Some variables were found to be independently associated with the incidence of high rates of exacerbations among all patients, as shown in figure 3A: isolation of *P. aeruginosa* (OR, 2.40; 95% CI 1.20 to 4.79), sex (OR,

0.52; 95% CI 0.27 to 0.99), BMI (OR, 1.09; 95% CI 1.01 to 1.19), onset of symptoms (OR, 1.03; 95% CI 1.00 to 1.05) and FEV₁ (OR, 0.95; 95% CI 0.90 to 0.99). In our subgroup analysis, the detection of *P. aeruginosa* was also a risk factor for high rates of exacerbations in groups with *P. aeruginosa* or other pathogens (OR, 2.98; 95% CI 1.53 to 5.79) and in groups with *P. aeruginosa* or negative (OR, 3.06; 95% CI 1.33 to 7.05) (figure 3B, C).

DISCUSSION

Our study found that *P. aeruginosa* was present in the sputum or BALF samples of 19.5% of patients with bronchiectasis, which is a finding that is similar to previous reports.^{10 20 21} In contrast to previous findings,^{3 10 20–23} our study found *P. aeruginosa* to be the most common pathogen (43.3%) among positive specimens (in which we found pathogens from sputum or bronchoalveolar). This disparity could be attributed to the differences in




Figure 2 Kaplan-Meier plot illustrating the survival of all patients with bronchiectasis. There are statistically significant differences in (A) and (B). (p(a)=0.045; p(b1)=0.017; p(b2)=0.414; p(b3)=0.125. P(a) means the difference between PA and non-PA groups; p(b1) means the difference between PA and negative groups; p(b2) means the difference between PA and others groups; p(b3) means the difference between others and negative groups).

Table 4 Variables associated with all-cause mortality among all patients in a Cox proportional hazard regression model

Variables	Unadjusted		Fully Adjusted	
	HR (95% CI)	P values	HR (95% CI)	P values
PA	1.65 (1.01 to 2.72)	0.048	3.07 (1.32 to 7.15)	0.009
Sex, M/F	2.35 (1.46 to 3.78)	<0.001	2.21 (1.09 to 4.49)	0.028
Age	1.08 (1.06 to 1.11)	<0.001	1.10 (1.06 to 1.14)	<0.001
BMI	0.86 (0.79 to 0.93)	<0.001	0.76 (0.68 to 0.86)	<0.001
Onset of symptoms	1.03 (1.01 to 1.04)	<0.001	1.02 (0.99 to 1.05)	0.081
mMRC score	1.35 (1.24 to 1.47)	<0.001	1.04 (0.85 to 1.27)	0.711
LCQ score	0.84 (0.78 to 0.90)	<0.001	1.00 (0.89 to 1.13)	0.979
FEV ₁ % of predicted (%)	0.98 (0.97 to 0.99)	0.001	0.99 (0.98 to 1.01)	0.185

Variables are adjusted for PA/non-PA status, sex, age, BMI, onset of symptoms, mMRC score, LCQ score and FEV₁ % of predicted (%). BMI, body mass index; FEV₁, forced expiratory volume in 1 s; LCQ, the Leicester Cough Questionnaire; mMRC, modified Medical Research Council; PA, *Pseudomonas aeruginosa*.

microbial distribution between different countries.²⁴ Moreover, our study found *Mycobacterium tuberculosis* to be present at a high prevalence of infection. Given our findings, the management of *P. aeruginosa* and the accurate assessment of its prognostic impact should be considered important in bronchiectasis treatment.

In our study, patients in the PA group had poorer lung function when compared with the non-PA group in terms of FEV₁ % (55.3% vs 75.4%, p<0.001), FVC % (74.2% vs 85.6%, p<0.001) and FEV₁/FVC (75.6% vs 88.3%, p<0.001). Davies *et al* have suggested that infection by *P. aeruginosa* occurs in patients with bronchiectasis with more severe pulmonary function impairment, but it does not itself influence the rate of pulmonary function decline either before or after adjustment for baseline disease severity.⁶ However, another study of 76 patients with bronchiectasis with 2 years of follow-up found chronic *P. aeruginosa* colonisation to be an independent factor associated with an accelerated decline in lung function.⁷ These disparities indicate that further validation from relevant large-scale studies is needed.

A recent review of 21 observational cohort studies by Finch *et al* showed that *P. aeruginosa* is associated with consistent and significant increases in all markers of disease severity, including mortality, hospitalisations and exacerbations. Patients with *P. aeruginosa* also had worse quality of life scores (based on St. George's Respiratory Questionnaire results), lung function and radiological severity compared with uninfected patients.²⁵ In accordance with these results, our fully adjusted analysis found that patients with *P. aeruginosa* were 3.07 times more likely to die than those without *P. aeruginosa*. Isolation of *P. aeruginosa* was also determined to be independently associated with high rates of exacerbations, as well as a lower quality of life as measured by mMRC and LCQ scoring. Thus, the prognostic value of *P. aeruginosa* isolation suggests the establishment of early treatment programmes to improve the overall prognosis of bronchiectasis.


As shown in figure 2(2B), we found no significant difference in mortality between the PA group and the others group (p=0.414) during the follow-up period. This result diverges from those of previous studies^{10 26} with

Table 5 Variables associated with all-cause mortality among the patients with PA or negative in a Cox proportional hazard regression model


Variables	Unadjusted		Fully Adjusted	
	HR (95% CI)	P values	HR (95% CI)	P values
PA	2.09 (1.17 to 3.75)	0.013	3.84 (1.17 to 12.62)	0.027
Sex, M/F	1.83 (1.03 to 3.27)	0.039	1.97 (0.70 to 5.50)	0.199
Age	1.08 (1.05 to 1.11)	<0.001	1.09 (1.03 to 1.15)	0.002
BMI	0.85 (0.77 to 0.94)	0.002	0.78 (0.66 to 0.91)	0.002
mMRC score	1.79 (1.43 to 2.26)	<0.001	1.42 (0.95 to 2.11)	0.086
Cystic	2.19 (1.09 to 4.42)	0.028	2.00 (0.59 to 6.80)	0.268
FEV ₁ % of predicted (%)	0.98 (0.96 to 0.99)	0.001	1.00 (0.98 to 1.02)	0.787

Variables are adjusted for PA/negative status, sex, age, BMI, onset of symptoms, mMRC score, LCQ score, cystic status and FEV₁ % of predicted (%).


BMI, body mass index; FEV₁, forced expiratory volume in 1 s; LCQ, the Leicester Cough Questionnaire; mMRC, modified Medical Research Council; PA, *Pseudomonas aeruginosa*.

A



Variables	OR (95% CI)	P
PA	2.40(1.20-4.79)	0.013
Sex, M/F	0.52(0.27-0.99)	0.045

(2)


Variables	OR (95% CI)	P
BMI	1.09(1.01-1.19)	0.038
Onset	1.03(1.00-1.05)	0.024
FEV1%	0.95(0.90-0.99)	0.025

B


Variables	OR (95% CI)	P
PA	2.98(1.53-5.79)	0.001
BMI	1.12(1.02-1.22)	0.016
Cystic	0.93(0.48-1.81)	0.828

C


Variables	OR (95% CI)	P
PA	3.06(1.33-7.05)	0.008
Age	1.04(1.00-1.07)	0.030
BMI	1.09(0.99-1.20)	0.067
Cystic	1.42(0.67-3.03)	0.365

Figure 3 Variables associated with high rates of exacerbations in a logistic regression model: (A) among all the patients, (B) among the patients in the PA or others group and (C) among patients in the PA or negative group.) BMI, body mass index; FEV₁, forced expiratory volume in 1s; PA, *Pseudomonas aeruginosa*.

several possible contributing factors. Given the difference in pathogen distribution between our sample and those taken from other countries, the distinct microbiology of our others group is likely to have influenced our results. Moreover, we assigned patients to the PA group based on the isolation of *P. aeruginosa* from sputum or BALF rather than *P. aeruginosa* colonisation, which is defined as the detection of two positive cultures at least 3 months apart over 12 months. We also excluded patients without sputum data and those whose follow-up duration was insufficient to have statistical significance, which carries some inherent selection bias. On the other hand, our findings showing that being in the PA group was a significant risk factor in high rates of exacerbations compared with being in the others group did match previous findings.

More relevant studies are needed to confirm the relationship between patients with *P. aeruginosa* and patients with other pathogens.

A study by Aliberti *et al* classified bronchiectasis into four clusters: *Pseudomonas*, other chronic infection, daily sputum and dry bronchiectasis. There were statistical significances in clinical outcomes between the four groups.²⁶ In agreement with their results, our findings show that patients with *P. aeruginosa* show greater disease severity, a more relevant inflammatory status, worsened clinical, functional and radiological characteristics, and poorer quality of life and long-term outcomes. A pairwise comparison of our three subgroups (PA, others and negative) also indicates the PA group as having the worst prognosis. Moreover, the present study provides a precise

estimate of *P. aeruginosa* prevalence and prognosis among Chinese patients with bronchiectasis.

Our study has several limitations. It is a single-centre study in a specialised hospital that enrolled a selected population of patients. In addition, we used ‘all-cause mortality’ as an endpoint instead of ‘bronchiectasis related mortality’, which may lead to the overestimation of the influence of *P. aeruginosa* infection. Besides, we used forward stepwise technique in statistical methods. Although both forward stepwise technique and backwards stepwise elimination consistently showed that the isolation of *P. aeruginosa* was related to higher mortality. There were also few differences which need to be researched further since none of the methods can completely eliminate the noise predictors. Additionally, there were 26 patients with bronchiectasis isolated with both *P. aeruginosa* and other organisms. We performed the appropriate statistical analysis and found that there were no significance differences between the patients isolated with *P. aeruginosa* and the patients with co-infections. This finding may have resulted from the small number of co-infection patients, and more rigorous studies are needed in the future. Furthermore, we were unable to define the PA group as suffering from chronic *P. aeruginosa* colonisation as the patients in this study came from all over the country, and we were unable to perform subsequent repeated sputum or BALF tests to confirm their state of bacterial colonisation.

In this study, the isolation of *P. aeruginosa* was related to worsened clinical symptoms, a more relevant inflammatory status, more severe radiographic manifestations, worse lung function and health-related quality life, more exacerbations and higher mortality. Pathogen detection from respiratory tract specimens is a significant indicator of disease prognosis. Large multicentre studies targeting the evaluation of the effect of eradication or long-term suppressive therapy on *P. aeruginosa* in bronchiectasis treatment are needed in the future.

Acknowledgements The authors thank Authur Zhang for his critical review of this manuscript.

Contributors HW, XBJ, BM and JFX designed the study, collected the data, developed the plan for analysis, analysed the data, drafted and revised the paper. CWL and HWL contributed substantially to the study design, data analysis and the drafting of the manuscript.

Funding This work was supported by the National Science Foundation of China (81670006); Shanghai Leading Talent Program (No. 2016036) and Shanghai Hospital Development Center Program (16CR3036A).

Competing interests None declared.

Patient consent Obtained.

Ethics approval Ethics Committee of Shanghai Pulmonary Hospital (k17-141)

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. *Thorax* 2010;65(Suppl 1):i1–58.
2. McShane PJ, Naureckas ET, Tino G, *et al.* Non-cystic fibrosis bronchiectasis. *Am J Respir Crit Care Med* 2013;188:647–56.
3. King PT, Holdsworth SR, Freezer NJ, *et al.* Microbiologic follow-up study in adult bronchiectasis. *Respir Med* 2007;101:1633–8.
4. McDonnell MJ, Jary HR, Perry A, *et al.* Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. *Respir Med* 2015;109:716–26.
5. Martínez-García MÁ, de Gracia J, Vendrell Relat M, *et al.* Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. *Eur Respir J* 2014;43:1357–67.
6. Davies G, Wells AU, Doffman S, *et al.* The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. *Eur Respir J* 2006;28:974–9.
7. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, *et al.* Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. *Chest* 2007;132:1565–72.
8. Miszkal KA, Wells AU, Rubens MB, *et al.* Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. *Thorax* 1997;52:260–4.
9. Boyton RJ, Altmann DM. Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology. *Annu Rev Pathol* 2016;11:523–54.
10. Chalmers JD, Goeminne P, Aliberti S, *et al.* The bronchiectasis severity index. An international derivation and validation study. *Am J Respir Crit Care Med* 2014;189:576–85.
11. Naidich DP, McCauley DI, Khouri NF, *et al.* Computed tomography of bronchiectasis. *J Comput Assist Tomogr* 1982;6:437–44.
12. Lynch DA, Newell JD, Tschomper BA, *et al.* Uncomplicated asthma in adults: comparison of CT appearance of the lungs in asthmatic and healthy subjects. *Radiology* 1993;188:829–33.
13. Qi Q, Li T, Li JC, *et al.* Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis. *Braz J Med Biol Res* 2015;48:715–24.
14. Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. *J Clin Microbiol* 1987;25:758–62.
15. Chastre J, Combes A, Luyt CE. The invasive (quantitative) diagnosis of ventilator-associated pneumonia. *Respir Care* 2005;50:797–807.
16. Bestall JC, Paul EA, Garrod R, *et al.* Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999;54:581–6.
17. Birring SS, Prudon B, Carr AJ, *et al.* Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax* 2003;58:339–43.
18. Murray MP, Turnbull K, MacQuarrie S, *et al.* Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. *Eur Respir J* 2009;34:125–31.
19. Zigmund AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361–70.
20. Loebinger MR, Wells AU, Hansell DM, *et al.* Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. *Eur Respir J* 2009;34:843–9.
21. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. *Eur J Intern Med* 2003;14:488–92.
22. Li AM, Sonnappa S, Lex C, *et al.* Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? *Eur Respir J* 2005;26:8–14.
23. Goeminne PC, Nawrot TS, Ruttens D, *et al.* Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. *Respir Med* 2014;108:287–96.
24. Li Z, Li JR, Gao JM. [Clinical evaluation of 136 inpatients with bronchiectasis in Peking Union Medical College Hospital]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2014;36:61–7.
25. Finch S, McDonnell MJ, Abo-Leyah H, *et al.* A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. *Ann Am Thorac Soc* 2015;12:1602–11.
26. Aliberti S, Lonni S, Dore S, *et al.* Clinical phenotypes in adult patients with bronchiectasis. *Eur Respir J* 2016;47:1113–22.